Open Menu

Meetings & Education

Research & Data

Practice & Patients

Career Development

News & Initiatives

Get Involved

Phase I dose escalation and expansion study of PRAME T-cell receptor (TCR) engineered IL15-transduced cord blood–derived natural killer (NK) cells in patients with recurrent and/or refractory melanoma (PRAMETIME-Mel).

download

Background:

For patients with relapsed and/or refractory metastatic melanoma (RRFM), there is a critical need to test novel strategies with improved anti-tumor response and safety profile. Adoptive cell therapy (ACT) has been recognized as a promising avenue for addressing the unmet need for more potent anti-tumor approaches. Allogeneic cord blood (CB)-derived natural killer (NK) cell therapies have emerged as a therapeutic alternative to adoptive T-cell therapies given decreased toxicity and feasibility as an “off-the-shelf” therapy, bypassing the manufacturing time and treatment delays associated with autologous T-cell products. PRAME (PReferentially expressed Antigen in MElanoma), a cancer-testis antigen expressed on approximately 95% of cutaneous melanomas and not expressed outside of immune-privileged sites such as the testis, ovary, placenta, and endometrium, is a promising target for allogeneic NK cells engineered with a T cell receptor (TCR) to selectively target melanoma cells. In contrast to autologous T cell therapies that require exogenous systemic IL-2 as a supportive factor, NK cells engineered to express IL-15 have been observed to have minimal side effects while significantly enhancing the in vivo expansion and persistence of the transduced NK cells. PRAME TCR/IL-15 NK, an engineered TCR NK cell therapy, has demonstrated efficacy against melanoma cell lines in vitro and in vivo and safety against normal human cell lines. Building upon these preclinical findings, we propose this trial to explore the safety and efficacy of PRAME TCR/IL-15 NK cells in patients with RRFM.

Methods:

This phase I, single-center, open-label trial will assess the safety, tolerability, and efficacy of PRAME TCR/IL-15 cells in patients with HLA A*02:01 positive RRFM, with no prospective PRAME testing. The primary endpoints are to determine the safety, tolerability, maximum tolerated dose and recommended phase II dose. The secondary endpoints are to assess response and survival. The study will be comprised of dose escalation (4 dose levels, with a dose level -1 in case of excessive toxicities observed in dose level 1) and dose expansion. A maximum of 39 patients will be enrolled, including 24 patients in the dose escalation cohort and up to 15 patients in the dose expansion cohort. Enrolled patients will receive lymphodepletion chemotherapy (fludarabine 30 mg/m2 and cyclophosphamide 500 mg/m2) on days -6 to -3, followed by a single dose of PRAME TCR/IL-15 NK cells on day 0. Longitudinal blood and tissue samples will be collected for correlative immune analysis.

Disclaimer

Author Details

Derrick Tao

The University of Texas MD Anderson Cancer Center, Houston, TX

Authors chevron_right

Associated Organizations chevron_right

Abstract Details

Meeting

2025 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

View MoreAbstract Disclosure
open_in_new

iframe

Download

iframe

Company Logo

Your Privacy

ASCO is committed to transparency regarding our websites and the ways we process data. When you visit our site, we may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, your location, or your device and is mostly used to make the site work as you expect it to and to personalize your web experience with us.

Because we respect your right to privacy, you can choose not to allow some or all types of cookies. Click on the different category headings to find out more about the types of cookies used on our websites and change your default settings to match your preferences. Please read these carefully. Blocking some types of cookies may impact your experience on the site, including our ability to personalize the content you receive from us.

For a full explanation of the personal and non-personal information we collect on our site, including how we use that information and your rights regarding that information, please review our Privacy Policy. Use of our website is also subject to our Terms of Use.

Allow All

Essential Website Cookies

Always Active

These cookies are necessary for the website to function and are sometimes referred to as “strictly necessary” cookies. They make sure the website delivers you information and services in an optimal way.

They are often set in response to an action you take, such as changing your cookie preferences, setting your privacy preferences, logging in to our website, asking the site to remember you on subsequent pages, or filling in forms. These cookies do not identify you personally.

You can set your browser to block or alert you about all cookies, including essential website cookies, but some parts of the site will not work as a result.

Cookies Details‎

Performance and Functionality Cookies

These cookies enhance the performance and functionality of our websites and the services we provide. For example, these cookies can keep track of your visitor session in between visits, enable you to share content through social media, use embedded media players, and use comment features. They also help us balance website load and improve site speed and performance.

All information these cookies collect is aggregated and therefore anonymous. These cookies may be set by us or by third party providers whose services we have added to our websites. These cookies are non-essential, but without these cookies, certain functionality or enhanced features may become unavailable.

Cookies Details‎

Personalization and Analytics Cookies

These cookies collect information that is used to help us understand how our websites and content are used, help us customize our websites and application for you in order to enhance your experience, and help us improve the content that ASCO creates to better meet our members’ and visitors’ needs. Examples include cookies that show us which content might be most popular with our visitors, understand browsing history of our users, understand the effectiveness of our own advertising, and enable us to recommend content to individual users based on their profile and activities on the website.

These cookies may be set by us or by third party providers whose services we have added to our websites.

These cookies are non-essential to the functionality of the site and may contain information that enables us or our third party providers to identify you and build a profile of your interests. Without these cookies, you will not be able to have a customized or personalized experience within our website.

Cookies Details‎

Advertising Cookies and Social Media Cookies

Advertising (or Targeting) cookies are third party cookies that may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant ads on other sites.

Social Media Cookies are cookies set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your activities across other sites and building a profile of your interests. This may impact the content and messages you see on other websites you visit.

These cookies and the data collected by the third parties may be combined with data from other users or data about your activity on other sites. While the data collected on our site is aggregate or non-personal, the data may be used by such third parties to link you on other platforms or otherwise identify you.

If you do not allow these cookies, you may experience less targeted advertising.

Cookies Details‎

Back Button

Search Icon

Filter Icon

Clear

checkbox labellabel

ApplyCancel

ConsentLeg.Interest

checkbox labellabel